Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 428,488
  • Shares Outstanding, K 47,769
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,850 K
  • EBIT $ -68 M
  • EBITDA $ -70 M
  • 60-Month Beta -0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.63

Options Overview Details

View History
  • Implied Volatility 199.60% (-60.70%)
  • Historical Volatility 71.02%
  • IV Percentile 4%
  • IV Rank 2.62%
  • IV High 728.63% on 02/05/26
  • IV Low 185.36% on 04/09/26
  • Expected Move (DTE 24) 2.13 (23.69%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 5
  • Volume Avg (30-Day) 174
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 813
  • Open Int (30-Day) 1,590
  • Expected Range 6.85 to 11.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 8
  • High Estimate $-0.22
  • Low Estimate $-0.29
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +16.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.87 +52.81%
on 03/23/26
9.40 -4.57%
on 04/17/26
+2.86 (+46.81%)
since 03/20/26
3-Month
4.14 +116.41%
on 01/21/26
9.40 -4.57%
on 04/17/26
+4.65 (+107.64%)
since 01/20/26
52-Week
1.13 +693.81%
on 05/15/25
9.40 -4.57%
on 04/17/26
+7.71 (+611.90%)
since 04/17/25

Most Recent Stories

More News
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates 

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials...

CLYM : 8.97 (-2.07%)
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical...

CLYM : 8.97 (-2.07%)
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Wave Life Sciences (WVE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM – Research Report) and Wave Life Sciences (WVE – Research Report) with bullish sentiments.Elevate...

CLYM : 8.97 (-2.07%)
WVE : 7.58 (+1.20%)

Business Summary

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell...

See More

Key Turning Points

3rd Resistance Point 9.71
2nd Resistance Point 9.52
1st Resistance Point 9.24
Last Price 8.97
1st Support Level 8.77
2nd Support Level 8.58
3rd Support Level 8.30

See More

52-Week High 9.40
Last Price 8.97
Fibonacci 61.8% 6.24
Fibonacci 50% 5.26
Fibonacci 38.2% 4.29
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.